BioMarin Pharmaceutical Inc. (0HNC.L)
USD 66.73
(-0.75%)
USD 66.73
(-0.75%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.89 Billion USD | 6.67% |
| 2022 | 1.77 Billion USD | 2.27% |
| 2021 | 1.73 Billion USD | -0.54% |
| 2020 | 1.74 Billion USD | 11.12% |
| 2019 | 1.56 Billion USD | 7.43% |
| 2018 | 1.45 Billion USD | -20.02% |
| 2017 | 1.82 Billion USD | 45.1% |
| 2016 | 1.25 Billion USD | -5.35% |
| 2015 | 1.32 Billion USD | 38.02% |
| 2014 | 962.55 Million USD | 5.99% |
| 2013 | 908.17 Million USD | 55.01% |
| 2012 | 585.88 Million USD | 10.41% |
| 2011 | 530.63 Million USD | -2.7% |
| 2010 | 545.36 Million USD | -8.34% |
| 2009 | 594.97 Million USD | -5.56% |
| 2008 | 630.02 Million USD | 0.39% |
| 2007 | 627.55 Million USD | 81.57% |
| 2006 | 345.63 Million USD | 26.71% |
| 2005 | 272.76 Million USD | -9.36% |
| 2004 | 300.94 Million USD | 117.31% |
| 2003 | 138.48 Million USD | 1047.08% |
| 2002 | 12.07 Million USD | -1.55% |
| 2001 | 12.26 Million USD | 76.73% |
| 2000 | 6.93 Million USD | 34.16% |
| 1999 | 5.17 Million USD | 146.29% |
| 1998 | 2.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.79 Billion USD | -4.83% |
| 2024 Q2 | 1.78 Billion USD | -1.0% |
| 2024 Q3 | 1437.79 Billion USD | -19.26% |
| 2023 Q3 | 1.86 Billion USD | 4.55% |
| 2023 FY | 1.89 Billion USD | 6.67% |
| 2023 Q4 | 1.89 Billion USD | 1.55% |
| 2023 Q1 | 1.77 Billion USD | 0.15% |
| 2023 Q2 | 1.78 Billion USD | 0.32% |
| 2022 Q4 | 1.77 Billion USD | 4.51% |
| 2022 Q3 | 1.69 Billion USD | 3.32% |
| 2022 FY | 1.77 Billion USD | 2.27% |
| 2022 Q1 | 1.67 Billion USD | -3.53% |
| 2022 Q2 | 1.64 Billion USD | -1.82% |
| 2021 Q3 | 1.71 Billion USD | 3.28% |
| 2021 Q4 | 1.73 Billion USD | 1.24% |
| 2021 FY | 1.73 Billion USD | -0.54% |
| 2021 Q1 | 1.64 Billion USD | -5.68% |
| 2021 Q2 | 1.65 Billion USD | 0.84% |
| 2020 FY | 1.74 Billion USD | 11.12% |
| 2020 Q3 | 2.1 Billion USD | 1.88% |
| 2020 Q1 | 1.48 Billion USD | -5.41% |
| 2020 Q2 | 2.06 Billion USD | 39.29% |
| 2020 Q4 | 1.74 Billion USD | -17.21% |
| 2019 Q3 | 1.48 Billion USD | 3.58% |
| 2019 FY | 1.56 Billion USD | 7.43% |
| 2019 Q1 | 1.49 Billion USD | 2.71% |
| 2019 Q2 | 1.43 Billion USD | -4.43% |
| 2019 Q4 | 1.56 Billion USD | 5.66% |
| 2018 Q1 | 1.78 Billion USD | -1.9% |
| 2018 FY | 1.45 Billion USD | -20.02% |
| 2018 Q4 | 1.45 Billion USD | -18.04% |
| 2018 Q3 | 1.78 Billion USD | 2.34% |
| 2018 Q2 | 1.73 Billion USD | -2.8% |
| 2017 Q3 | 1.76 Billion USD | 44.33% |
| 2017 Q1 | 1.16 Billion USD | -6.99% |
| 2017 FY | 1.82 Billion USD | 45.1% |
| 2017 Q2 | 1.22 Billion USD | 4.69% |
| 2017 Q4 | 1.82 Billion USD | 3.24% |
| 2016 Q1 | 1.37 Billion USD | 3.63% |
| 2016 Q4 | 1.25 Billion USD | 5.1% |
| 2016 FY | 1.25 Billion USD | -5.35% |
| 2016 Q3 | 1.19 Billion USD | 2.28% |
| 2016 Q2 | 1.16 Billion USD | -15.04% |
| 2015 Q1 | 1.23 Billion USD | 28.12% |
| 2015 Q2 | 1.29 Billion USD | 4.74% |
| 2015 Q4 | 1.32 Billion USD | -0.28% |
| 2015 FY | 1.32 Billion USD | 38.02% |
| 2015 Q3 | 1.33 Billion USD | 3.13% |
| 2014 Q2 | 883.71 Million USD | 0.35% |
| 2014 FY | 962.55 Million USD | 5.99% |
| 2014 Q3 | 931.99 Million USD | 5.46% |
| 2014 Q4 | 962.55 Million USD | 3.28% |
| 2014 Q1 | 880.6 Million USD | -3.04% |
| 2013 Q3 | 344.04 Million USD | 0.23% |
| 2013 Q1 | 348.14 Million USD | -40.58% |
| 2013 Q2 | 343.26 Million USD | -1.4% |
| 2013 FY | 908.17 Million USD | 55.01% |
| 2013 Q4 | 908.17 Million USD | 163.97% |
| 2012 FY | 585.88 Million USD | 10.41% |
| 2012 Q4 | 585.88 Million USD | 6.1% |
| 2012 Q1 | 525.13 Million USD | -1.04% |
| 2012 Q2 | 532.1 Million USD | 1.33% |
| 2012 Q3 | 552.18 Million USD | 3.77% |
| 2011 Q4 | 530.63 Million USD | 1.94% |
| 2011 FY | 530.63 Million USD | -2.7% |
| 2011 Q3 | 520.53 Million USD | -5.03% |
| 2011 Q1 | 543.3 Million USD | -0.38% |
| 2011 Q2 | 548.08 Million USD | 0.88% |
| 2010 Q3 | 658.86 Million USD | 5.83% |
| 2010 FY | 545.36 Million USD | -8.34% |
| 2010 Q2 | 622.55 Million USD | 0.26% |
| 2010 Q1 | 620.96 Million USD | 4.37% |
| 2010 Q4 | 545.36 Million USD | -17.23% |
| 2009 Q4 | 594.97 Million USD | 5.21% |
| 2009 FY | 594.97 Million USD | -5.56% |
| 2009 Q1 | 626.34 Million USD | -0.58% |
| 2009 Q2 | 561 Million USD | -10.43% |
| 2009 Q3 | 565.5 Million USD | 0.8% |
| 2008 Q4 | 630.02 Million USD | 1.43% |
| 2008 Q3 | 621.13 Million USD | -1.18% |
| 2008 Q1 | 618.53 Million USD | -1.44% |
| 2008 Q2 | 628.52 Million USD | 1.62% |
| 2008 FY | 630.02 Million USD | 0.39% |
| 2007 FY | 627.55 Million USD | 81.57% |
| 2007 Q1 | 285.05 Million USD | -17.53% |
| 2007 Q2 | 614.03 Million USD | 115.41% |
| 2007 Q3 | 616.51 Million USD | 0.4% |
| 2007 Q4 | 627.55 Million USD | 1.79% |
| 2006 Q2 | 419.82 Million USD | -5.06% |
| 2006 Q3 | 344.95 Million USD | -17.83% |
| 2006 Q1 | 442.22 Million USD | 62.13% |
| 2006 FY | 345.63 Million USD | 26.71% |
| 2006 Q4 | 345.63 Million USD | 0.2% |
| 2005 FY | 272.76 Million USD | -9.36% |
| 2005 Q3 | 274.22 Million USD | -1.25% |
| 2005 Q2 | 277.68 Million USD | 2.4% |
| 2005 Q1 | 271.16 Million USD | -9.89% |
| 2005 Q4 | 272.76 Million USD | -0.53% |
| 2004 FY | 300.94 Million USD | 117.31% |
| 2004 Q1 | 140.52 Million USD | 1.47% |
| 2004 Q2 | 304.22 Million USD | 116.49% |
| 2004 Q3 | 298.06 Million USD | -2.02% |
| 2004 Q4 | 300.94 Million USD | 0.97% |
| 2003 Q4 | 138.48 Million USD | -2.8% |
| 2003 Q3 | 142.48 Million USD | -1.02% |
| 2003 Q2 | 143.94 Million USD | 736.18% |
| 2003 Q1 | 17.21 Million USD | 42.59% |
| 2003 FY | 138.48 Million USD | 1047.08% |
| 2002 Q1 | 12.93 Million USD | 5.5% |
| 2002 FY | 12.07 Million USD | -1.55% |
| 2002 Q4 | 12.07 Million USD | 7.23% |
| 2002 Q2 | 11.19 Million USD | -13.48% |
| 2002 Q3 | 11.25 Million USD | 0.58% |
| 2001 Q4 | 12.26 Million USD | 96.65% |
| 2001 Q2 | 5.32 Million USD | 44.44% |
| 2001 Q1 | 3.68 Million USD | -46.91% |
| 2001 Q3 | 6.23 Million USD | 17.2% |
| 2001 FY | 12.26 Million USD | 76.73% |
| 2000 Q2 | 2.89 Million USD | -39.19% |
| 2000 Q3 | 3.67 Million USD | 26.88% |
| 2000 FY | 6.93 Million USD | 34.16% |
| 2000 Q1 | 4.75 Million USD | -7.99% |
| 2000 Q4 | 6.93 Million USD | 88.97% |
| 1999 Q3 | 5.7 Million USD | -83.24% |
| 1999 Q2 | 34 Million USD | 1900.0% |
| 1999 Q1 | 1.7 Million USD | 0.0% |
| 1999 FY | 5.17 Million USD | 146.29% |
| 1999 Q4 | 5.17 Million USD | -9.26% |
| 1998 FY | 2.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -1159.566% |
| Dynavax Technologies Corporation | 375.02 Million USD | -403.982% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -287.734% |
| Perrigo Company plc | 6.04 Billion USD | 68.714% |
| Illumina, Inc. | 4.36 Billion USD | 56.71% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 96.357% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -865.604% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 97.255% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 90.811% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -636.923% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 73.406% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -4968.256% |
| Waters Corporation | 3.47 Billion USD | 45.634% |
| Biogen Inc. | 12.04 Billion USD | 84.309% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -2192.837% |
| Evolus, Inc. | 209.68 Million USD | -801.369% |
| Adicet Bio, Inc. | 37.12 Million USD | -4991.74% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -2648.81% |
| bluebird bio, Inc. | 424.62 Million USD | -345.112% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -186.029% |
| FibroGen, Inc. | 585.72 Million USD | -222.685% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 61.569% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -5272.965% |
| Homology Medicines, Inc. | 118.53 Million USD | -1494.538% |
| Geron Corporation | 146.12 Million USD | -1193.432% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 53.338% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -205.98% |
| Myriad Genetics, Inc. | 312.9 Million USD | -504.044% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -9316.84% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -653.586% |
| Zoetis Inc. | 9.29 Billion USD | 79.666% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -3743.448% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 46.083% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 63.298% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -3801.443% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 27.4% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -613.942% |
| Verastem, Inc. | 71.18 Million USD | -2555.13% |
| Nektar Therapeutics | 267.04 Million USD | -607.763% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -375.774% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -4598.588% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 21.419% |
| OPKO Health, Inc. | 622.47 Million USD | -203.633% |
| Exelixis, Inc. | 678.44 Million USD | -178.586% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -85.408% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -1546.216% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -14979.416% |
| uniQure N.V. | 624.01 Million USD | -202.884% |
| Imunon, Inc. | 8.53 Million USD | -22056.617% |
| Blueprint Medicines Corporation | 918.64 Million USD | -105.745% |
| Insmed Incorporated | 1.66 Billion USD | -13.738% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -14.586% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1398.865% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1017.813% |
| Incyte Corporation | 1.59 Billion USD | -18.702% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -59.418% |